BioMed Realty

BioMed Realty

Owns and manages life-science real estate.

Overview

BioMed Realty is a real estate investment trust that acquires, develops, owns, and manages laboratory and office space for the life science industry, with properties in the United States and United Kingdom. It earns income by signing long-term leases with high-quality tenants such as pharmaceutical and biotechnology companies, research institutions, and government agencies, and provides ongoing property and asset management. The company differentiates itself by being one of the largest private owners and operators of life science real estate, offering specialized facilities in major innovation hubs and a stable, high-grade tenant base. Its goal is to deliver steady, long-term rental revenue while growing a premier portfolio that supports biotech and pharmaceutical ecosystems.

About BioMed Realty

Simplify's Rating
Why BioMed Realty is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Real Estate

Healthcare

Company Size

201-500

Company Stage

N/A

Total Funding

$598.6M

Headquarters

San Diego, California

Founded

2004

Get referred to BioMed Realty

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Biogen’s 585 Broadway project and TransMedics’ headquarters lease lock in long-duration cash flow.
  • Babraham Research Campus fully leased its newest building in February 2026, validating UK demand.
  • Gateway of Pacific won a 2026 BOMA TOBY award, strengthening tenant confidence and pricing power.

What critics are saying

  • In July 2026, BioMed surrendered 1000 Washington Street and 321 Harrison Avenue to lenders.
  • Boston concentration remains dangerous; one-third of BioMed’s portfolio sits in the soft South End/Cambridge market.
  • If lease-up stalls again, 2027 refinancing pressure hits development-heavy campuses and blunts growth.

What makes BioMed Realty unique

  • 17.3 million square feet spans Boston, Bay Area, San Diego, Seattle, Cambridge, and U.K.
  • BioMed secured a 16-year, 498,000-square-foot TransMedics lease at Assembly Innovation Park in January 2026.
  • BioMed’s Blackstone-backed capital base supports large, mission-critical, build-to-suit lab campuses.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$598.6M

Above

Industry Average

Funded Over

0 Rounds

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

Paid Family Leave Benefits

401(k) Retirement Plan

Tuition Reimbursement

Flexible Spending Accounts

Commuter Benefits

Lifestyle Spending Account

Pet Insurance

ID Theft Insurance

Legal Insurance

Employee Assistance Program

100% Employer-Paid Life & AD&D Insurance

Short and Long Term Disability

Company News

AnaptysBio
Apr 13th, 2026
AnaptysBio Secures $40 Million Series D Financing | AnaptysBio, Inc.

Enables Advancement of First-In-Class Anti-Inflammatory Antibody Programs Through Key Clinical Studies   SAN DIEGO, California — AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the completion of an

Recently Posted Jobs

Sign up to get curated job recommendations

BioMed Realty is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →